Taylor Boyd - 26 Feb 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Business Officer
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Issuer symbol
AVTX
Transactions as of
26 Feb 2026
Net transactions value
$0
Form type
4
Filing time
02 Mar 2026, 16:22:37 UTC
Previous filing
06 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boyd Taylor Chief Business Officer C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE /s/ Christopher Sullivan, Attorney-in-Fact 02 Mar 2026 0002090172

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +95,000 $0.000000 95,000 26 Feb 2026 Common Stock 95,000 $17.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.